The Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors

Tami Livnat¹, Alfiça Sehgal², Kun Qian², Huy Van Nguyen², Benny Sorensen³, Gili Kenet¹
Introduction
Treatment Options for Patients with Inhibitors

Patients with hemophilia with high responding inhibitors are treated with bypassing agents.

Bypassing agents aim to enable the burst of thrombin generation as the final common mediator for clot formation, despite the absence of FVIII or FIX.

The most commonly used bypassing agents are recombinant activated FVII (rFVIIa; i.e. NovoSeven) and activated prothrombin complex concentrate (aPCC; i.e. FEIBA).

Recently, new non-factor replacement therapies have emerged for patients with hemophilia, including patients with inhibitors.
Fitusiran
Investigational RNAi Therapeutic for Treatment of Hemophilia

**Fitusiran (ALN-AT3)**
- SC-administered small interfering RNA (siRNA) therapeutic targeting antithrombin (AT)
  - Non-biologic, chemically-synthesized, with targeting ligand to specifically deliver to liver—site of AT synthesis
  - Harnesses natural RNA interference (RNAi) mechanism for regulation of plasma AT levels

**Therapeutic hypothesis**
- Hemophilia A and B are bleeding disorders characterized by ineffective clot formation due to insufficient thrombin generation
- Fitusiran is designed to lower AT, with goal of promoting sufficient thrombin generation to restore hemostasis and prevent bleeding
  - Observation of ameliorated bleeding phenotype in patients with co-inheritance of thrombophilic traits in hemophilia
  - Supported by pre-clinical data and emerging Phase 1 clinical results

Aims

Patients with hemophilia with inhibitors treated with fitusiran may experience breakthrough bleeding episodes.

As bleeding episodes in inhibitor patients are treated with bypassing agents, we aimed to predict the effect of bypassing agents in the background of fitusiran therapy.

Thrombin generation was evaluated in plasma of patients with hemophilia A and B with inhibitors in the presence of bypassing agent and reduced antithrombin activity.
Methods

Plasma samples from patients with severe hemophilia A (HA) and hemophilia B (HB) with high responding inhibitors were spiked with anti-AT antibody to target reduction of AT activity by approximately 50% or 90%, to model fitusiran treatment.

Patient plasma was spiked with rFVIIa (1.25 and 2.5 μg/ml corresponding to doses of 45 and 90 mcg/kg, respectively\(^1,^2\)) or aPCC (0.5 and 1 U/ml corresponding to doses of 37.5 and 75 U/kg, respectively\(^1,^2\)) either alone or in combination with AT activity reduction.

TG was measured by calibrated automated TG assay using 1 pM tissue factor and 4 μM phospholipid.
Results
Demographics and AT Lowering

15 patients with high responding inhibitors provided plasma samples
- 12 HA patients
- 3 HB patients
- Median age = 6 (range 1-50)

AT lowering, in samples from 14 patients, with anti-AT antibody targeting 50 or 90% lowering AT lowering was similar to fitusiran (~80% lowering)

Antithrombin lowering with anti-AT antibody in samples from patients with hemophilia A or B with inhibitors

Antithrombin lowering with fitusiran in patients with hemophilia A or B with inhibitors

AT, antithrombin; HA, hemophilia A; HB, hemophilia B
Results
Antithrombin Reduction Improved Thrombin Generation in Hemophilia Plasma

Median baseline peak thrombin generation was substantially lower in patients with hemophilia compared to healthy volunteers. Decrease in antithrombin activity resulted in a corresponding improvement in thrombin generation.
Results

Thrombin Generation Further Improved with Addition of rFVIIa to AT Reduction and Does not Exceed Healthy Volunteer Range

Addition of 45 and 90 mcg/kg rFVIIa to the plasma samples induced an additive increase in peak thrombin generation
Results

Thrombin Generation Further Improved with Addition of aPCC to AT Reduction and Does Not Exceed Healthy Volunteer Range

 Addition of 38 and 75 U/kg aPCC to the plasma samples induced higher peak thrombin generation
Limitations

Small, heterogeneous sample size makes this challenging to generalize broadly to hemophilia subpopulations

TG was assayed in platelet poor plasma samples, which may underestimate the level of TG for rFVIIa, since platelets play an important role in its pharmacodynamics effects.
Summary

Enhanced thrombin generation was achieved with bypassing agents in the context of reduced plasma AT activity in this ex vivo study.

Peak thrombin levels did not exceed the normal range, either with AT lowering alone or with the addition of bypassing agents.

These data suggests that bypassing agents may potentially be used in conjunction with AT reduction.

Further clinical investigations are required to better understand the implications, relevance, and translatability of these ex vivo findings to clinical practice.